Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients
| Autor: | Peter G A, Hompes, Frank J, Broekmans, Diederik A, Hoozemans, Roel, Schats, Rien, Crooij |
|---|---|
| Přispěvatelé: | Obstetrics and gynaecology, Neuroscience Campus Amsterdam 2008, ICaR - Ischemia and repair |
| Rok vydání: | 2008 |
| Předmět: |
Adult
endocrine system medicine.medical_specialty Menotropins Pregnancy Rate medicine.drug_class medicine.medical_treatment Fertilization in Vitro Biology Intracytoplasmic sperm injection Andrology Follicle-stimulating hormone Ovulation Induction Pregnancy Internal medicine medicine Humans Sperm Injections Intracytoplasmic In vitro fertilisation Patient Selection Obstetrics and Gynecology Embryo Transfer medicine.disease Recombinant Proteins Embryo transfer Menopause Pregnancy rate Endocrinology Reproductive Medicine Fertilization Female Follicle Stimulating Hormone Gonadotropin Maternal Age |
| Zdroj: | Fertility and Sterility, 89(6), 1685-1693. Elsevier Inc. Hompes, P G A, Broekmans, F J, Hoozemans, D A & Schats, R 2008, ' Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients ', Fertility and Sterility, vol. 89, no. 6, pp. 1685-1693 . https://doi.org/10.1016/j.fertnstert.2007.05.039 |
| ISSN: | 0015-0282 |
| DOI: | 10.1016/j.fertnstert.2007.05.039 |
| Popis: | Objective To compare the effectiveness of highly purified hMG with recombinant FSH (rFSH) in IVF–intracytoplasmic sperm injection patients who were treated with a GnRH agonist. Design An open-label, prospective, randomized comparison of fixed gonadotropin regimens. Setting Eighteen Dutch IVF centers. Patient(s) Six hundred twenty-nine patients who were selected for IVF–intracytoplasmic sperm injection. Intervention(s) Patients were randomized to receive either highly purified hMG or rFSH in a fixed dosage of 150 IU/d after GnRH-agonist suppression (long protocol). Main Outcome Measure(s) Ongoing pregnancy rate per started cycle. Difference between the two treatment groups was tested by using odds ratios, including the 95% confidence limits (intention-to-treat sample), and by using the Fisher's exact test (per-protocol sample). Result(s) The ongoing pregnancy rates per started cycle were 26.3% and 25.2% for highly purified hMG and rFSH, respectively (no statistically significant difference). Treatment with highly purified hMG resulted in statistically significantly fewer oocytes (n = 7.8) than did treatment with rFSH (n = 10.6). There were no differences with respect to fertilization rates and implantation rates. Cycles with highly purified hMG were statistically significantly less often canceled as a result of ovarian hyperresponse (2.0% vs. 6.0% for highly purified hMG and rFSH, respectively). Conclusion(s) Compared with rFSH, highly purified hMG did not result in superiority in ongoing pregnancy rates in first-cycle IVF–intracytoplasmic sperm injection patients who were treated with a fixed dosage of 150 IU of gonadotropin per day. Compared with rFSH, treatment with highly purified hMG resulted in retrieval of fewer oocytes, a lower incidence of hyperresponse, and comparable pregnancy rates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|